CHDR2118 Trial
- Duration
- Type of research
- Klinische trial - fase I
In this phase 1 clinical trial, we are studying the effects of the drug DNL343 in people with ALS. The aim of this study is to determine how safe and tolerable the new drug is, what effects it has on people with ALS, and how the body absorbs and processes it. This study is sponsored by Denali Therapeutics Inc.
DNL343
In people with ALS, a certain mechanism in body cells, called the integrated stress response (ISR), appears to be overactive. When this mechanism remains active for a prolonged period, it can lead to loss of cellular function and possibly even the degeneration of nerves that control muscle activity. Inhibiting the ISR with investigational drugs seems to protect nerves and has shown positive effects on physical function in various animal and laboratory studies.
The investigational drug inhibits the ISR and may therefore be beneficial for treating ALS. However, it has never been administered to people with ALS before. It has only been tested in healthy volunteers and laboratory animals. Outside of this study, doctors cannot prescribe or use the investigational drug.